Prospective Observational Pilot Study of Myo-inositol and D-chiro-inositol (Femsol) in Women with Polycystic Ovary Syndrome in Tobruk, Libya
DOI:
https://doi.org/10.54361/LJMR.20.2.44Keywords:
PCOS, insulin resistance, hyperandrogenism, AMH, LH/FSH ratio, metabolic dysfunction, treatment efficacyAbstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by reproductive, hormonal, and metabolic dysfunction. Current treatments often show limited efficacy and may be associated with adverse effects Objective To evaluate the efficacy of Femsol in improving clinical symptoms, hormonal profiles, and metabolic parameters in women with PCOS Methods: “A prospective observational pilot study was conducted on 100 women diagnosed with PCOS. Pre- and post-treatment parameters were compared using paired statistical analyses, Pre- and post-treatment parameters were compared using paired statistical tests. Due to partial reliance on simulated data and absence of a control group, findings are considered exploratory. Result: Femsol demonstrated consistent improvements across clinical and biochemical domains. Symptom reduction ranged from 67.6% to 70.0%. Significant reductions were observed in AMH (−39.7%), LH/FSH ratio (−36.5%), testosterone (−31.0%), and HOMA-IR (−30.0%). Approximately 70% of participants met treatment response criteria. Conclusion: Femsol appears to be a promising “Femsol showed promising preliminary effects on clinical, hormonal, and metabolic parameters in women with PCOS. Further randomised controlled studies are required to confirm these findings as a therapeutic option for PCOS. However, randomised controlled trials are required to confirm these findings.
Downloads
References
1. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
2. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011;3:25-35.
3. Dewailly D, Lujan ME, Carmina E, et al. Polycystic ovarian morphology. Hum Reprod Update. 2014;20(3):334-352.
4. Diamanti-Kandarakis E, Dunaif A. Insulin resistance in PCOS. Endocr Rev. 2012;33(6):981-1030.
5. Dunaif A. Insulin resistance and PCOS. Endocr Rev. 1997;18(6):774-800.
6. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-284.
7. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-231.
8. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.
9. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347-363.
10. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467-520.
11. Tang T, Lord JM, Norman RJ, et al. Metformin for women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2012;(5): CD003053.
12. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364-379.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Inas.A. yhea, wardah naji , Sameerah abduljawad , Radia A almutkhatri, Fayazah M Mohammed, Sarah M makhzoum, Bilqyas A ashour, Maqboulah O amtoubil (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
https://portal.issn.org/resource/ISSN/2413-6069
